The new concept of medicine seeks end-stage prostate cancer


Micrograph showing prostate acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

A new class of drugs is successfully targeting treatment-resistant prostate cancers and prolonging patients ’lives. Treatment provides beta radiation directly to tumor cells, is well tolerated by patients, and keeps them alive for longer than standard care. He found a phase 3 trial to be presented today at the congress of the European Association of Urology, UAE21.

Despite the progress made in in recent years, resistant to metastatic castration it remains treatable and fatal. The new treatment, known as Lu-PSMA-617, takes a new approach to a molecule called PSMA, which is known to increase on the surfaces of the , destroying them and their surrounding microenvironment.

Professor Johann de Bono, Professor of Experimental Cancer Medicine at the London Cancer Research Institute and Consultant Medical Oncologist of the Royal Marsden NHS Foundation Trust, and Professor Ken Herrmann, Director of the Nuclear Medicine Clinic University Hospital of Essen, Germany, and an international team of researchers set out to test whether Lu-PSMA-617 was more effective than standard care and recruited 831 patients with metastatic castration-resistant prostate cancer among June 2018 and October 2019. Patients were randomly assigned to receive treatment plus the standard. care or standard care alone.

They report that treatment significantly improved patient survival by an average of four months, compared with standard treatment. The mean survival time was 15.3 for the treatment group and 11.3 months for those receiving standard care. Progression-free survival, or the time before a patient’s tumor worsened, was also longer with treatment: an average of 8.7 months compared with 3.4 months for those with .

The trial also compared side effects, finding that health-related quality of life was not adversely affected and the team concludes that it is an effective and safe drug that can improve care for patients with this prostate cancer. advanced.

Professor Ken Herrmann says: “This is a completely new therapeutic concept; a precision medicine that transmits radiation directly to a high-incidence tumor. The treatment was well tolerated by the patients and they had an average survival of four months. more with a good quality of life Lu-PSMA-617 can improve the life of many men with and their families. “

Professor Johann de Bono says: “Our findings show that this powerful radioactive drug can accurately deliver radiation to cancer cells and destroy them, prolonging the lives of patients. I hope men with elevated PSMA tumors can benefit -so soon of this so innovative treatment “. Treatment is currently being evaluated by the National Institute for Health and Care Excellence (NICE) for use in the NHS in England and Wales. “

“The use of the PSMA molecule to target prostate cancer cells directly is the beginning of a new era of precision medicine in both urology diagnosis and therapy,” says the Professor Peter Albers, Head of the Department of Urology at the University of Dusseldorf and President of the UAE Office. “LU-PSMA-617 was tested in so-called end-stage disease and still showed superiority and this paves the way for studies to treat patients in earlier stages. We have seen similar success in diagnosis, using this molecule to This targeted approach will revolutionize the way we approach the treatment of men with prostate cancer in the future. ”

Radioligand therapy slows advanced PSMA + prostate cancer

Citation: A new drug concept seeks end-stage prostate cancer (2021, July 11) retrieved July 11, 2021 from stage-prostate-cancer.html

This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link